Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apnea First-ever type 2 diabetes and obesity phase 3 study results for retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1(GLP-1), and glucagon triple hormone receptor agonist, were announced today. The findings demonstrated positive outcomes in people living with obesity and type 2 diabetes, as well as improvements in major complications, including obstructive sleep apnea and knee osteoarthritis